Related Experiment Video

Updated: Aug 10, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider

Richard Vile1, Dale Ando, David Kirn

  • 1Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota, USA.

Cancer Gene Therapy
|January 11, 2003
PubMed

Insights

Replication-selective oncolytic viruses show promise for cancer therapy. This review discusses challenges and solutions for improving virotherapy effectiveness and safety.

Area of Science:

  • Oncology
  • Virology
  • Biotechnology

Background:

  • Virotherapy, using replication-selective oncolytic viruses, has rapidly advanced in cancer treatment over the past decade.
  • Early clinical trials with first-generation agents revealed significant challenges, tempering initial enthusiasm.
  • Despite hurdles, rapid progress is being made in developing novel solutions for this therapeutic approach.

Purpose of the Study:

  • To discuss the identified hurdles in oncolytic virus therapy.
  • To explore proposed solutions and ongoing improvements for virotherapy.
  • To address unique safety and regulatory considerations for oncolytic virus applications.

Main Methods:

  • Review of current literature on replication-selective oncolytic viruses.
  • Analysis of clinical trial outcomes and identified challenges.
  • Discussion of proposed strategies for overcoming therapeutic limitations.

Main Results:

  • Significant hurdles in oncolytic virus therapy have been identified.
  • Novel solutions and improvements are being rapidly developed.
  • Unique safety and regulatory issues require careful consideration.

Conclusions:

  • Virotherapy holds significant potential but faces challenges.
  • Ongoing research focuses on overcoming these hurdles for improved efficacy.
  • Addressing safety and regulatory aspects is crucial for clinical translation.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.